All In Biotech

Drug Trial Radar · NCT07705568

An Open-label Safety, Tolerability and Exploratory Efficacy Clinical Trial of PST-611 in Geographic Atrophy

An Open-label Multiple Dose Safety, Tolerability and Exploratory Efficacy Clinical Trial of PST-611 in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration

Last checked: Nov 19, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Jun 2028

Study completion Jun 2028

Sponsor

Lead sponsor
EyevensysIndustry
Sponsor type
Industry
First posted
Jul 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goals of this interventional study are (1) to evaluate the safety and tolerability of multiple doses of PST-611 in men and women over the age of 65 with geographic atrophy secondary to age-related macular degeneration and (2) to assess efficacy of multiple doses of PST-611 by assessing retinal morphology and visual function changes over time. Participants will: * receive one dose every 20 weeks, for a total of 3 doses. * will be followed up for a total of 52 weeks following the first PST-611 dose.

Conditions

  • Geographic Atrophy
  • Age - Related Macular Degeneration (AMD)

Interventions

  • PST-611Biological

    PST-611 is a naked plasmid DNA encoding human transferrin administered into the ciliary muscle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency and severity of ocular and non-ocular adverse events (Safety and Tolerability)Time frame: Screening to week 52

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • CHU de Grenoble-Hôpital Michallon

    Grenoble, France, France

  • Hôpital Lariboisière

    Paris, France, France

  • Hôpital Cochin

    Paris, France, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.